Harki to Serve as Co-Investigator and Deputy Director of Medicinal Chemistry and DMPK
May 27, 2022
Minneapolis, Minn
May. 27, 2022
The University of Minnesota has received $66 million from the National Institute of Allergy and Infectious Diseases (NIAID) to establish a center to develop antiviral drugs for pandemic-level viruses, including SARS-CoV-2.
The Midwest Antiviral Drug Discovery (AViDD) Center is part of a network of nine national centers established by NIAID in response to the public health emergency caused by COVID-19.
The hub of the Center is located in Minnesota with two-thirds of the scientists located in the broader Midwest. Dr. Daniel Harki, Northrop Professor in the College of Pharmacy’s Department of Medicinal Chemistry, serves as co-Investigator and Deputy Director of the Medicinal Chemistry and Drug Metabolism and Pharmacokinetics (DMPK) Core.
Read the University’s official press release about the grant and establishment of the center.
